Abstract 98P
Background
We investigate whether the continuation of adjuvant treatment and clinical course of adjuvant treatment would be affected by the development of postoperative complications in the patients who underwent curative resection for colon cancer in a pooled analysis of two large phase III studies performed in Japan.
Methods
The study examined the patients who enrolled in 1303, phase III comparing the efficacy of 6 months and 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer patients and in 882, a phase III to confirm tolerability oxaliplatin, fluorouracil, and l-leucovorin in Japanese stage II/III colon cancer patients. In this study, POCs were defined as the following major surgical complication; Anastomotic leakage, Pneumonia, Bowel obstruction/ileus, Surgical site infection, Postoperative bleeding, Urinary tract infection, and Fistula. The patients were classified as those with POCs (C group) and those without POCs (NC group).
Results
2095 patients were examined in the present study. POCs were observed in 169 patients (8.1%). The overall survival rates at five-year after surgery was 75.3% in the C-group and 86.5% in NC-group, respectively (p=0.0017). Hazard ratio of POCs for OS was 1.77 (95% confidence interval, 1.23 to 2.54; p=0.0017). Time to adjuvant treatment failure (TTF) of adjuvant chemotherapy was almost similar; 6-months TTF was 68.6% in C-group and 67.1% in NC-group. Dose reduction rate of adjuvant chemotherapy and adjuvant treatment suspension rate were also similar between C-group and NC-group (45.0% vs 48.7%, p=0.3520 and 52.7% vs 55.0%, p=0.5522, respectively).
Conclusions
POCs were associated with the poor prognosis, while the POCs did not affect the intensity of adjuvant chemotherapy. These results suggested that the POCs itself have negative survival impact.
Clinical trial identification
Editorial acknowledgement
This study was supported, in part, by the non-profit organization Epidemiological & Clinical Research Information Network (ECRIN).
Legal entity responsible for the study
Japanese Foundation for Multidisciplinary Treatment of Cancer.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract